Targeted Therapy for Cancer

Hardcover | December 12, 2002

EditorKonstantinos N. Syrigos, Kevin Harrington

not yet rated|write a review
The quest for therapeutic specificity is implicit in all branches of medicine. In cancer treatment, where the therapeutic modality is a cytotoxic agent such as radiotherapy or chemotherapy, such specificity is of paramount importance. The growing realisation that current therapeutic optionsare likely to yield no more than incremental improvements in outcome has fuelled the search for more active targeted approaches. This book discusses the more archetypal systemic targeted therapies, such as those employing monoclonal antibodies or liposomes, but also includes strategies, such as photodynamic therapy and boron neutron capture therapy, that rely on direct physical targeting of disease. The explosion in ourunderstanding of the molecular biology of cancer in recent years has led to the identification of a number of new potential therapeutic targets. These factors, combined with the likelihood that yet more valuable information will be gleaned from the Human Genome Project, mean that inevitably, significant clinical activity in this arena is anticipated in the coming years with the very real prospect that gene therapy approaches may find anestablished role in the standard treatment of some of the common cancers. This book brings together the very latest research in this field from an international group of experts and will prove invaluable for molecular oncologists, cancer researchers and those involved with clinical trials as well as providing a reference for oncologists who are beginning to use some ofthese therapies in everyday clinical practice.

Pricing and Purchase Info

$585.49 online
$795.00 list price (save 26%)
Ships within 1-3 weeks
Ships free on orders over $25

From the Publisher

The quest for therapeutic specificity is implicit in all branches of medicine. In cancer treatment, where the therapeutic modality is a cytotoxic agent such as radiotherapy or chemotherapy, such specificity is of paramount importance. The growing realisation that current therapeutic optionsare likely to yield no more than incremental i...

KN Syrigos, MD, PhD, Consultant Medical Oncologist, Head, Oncology Unit, 3rd Department of Medicine, Athens Medical School, Sotiria General Hospital, Athens, Greece Kevin J Harrington, FRCR, Melucular Medicine Program, Mayo Clinic, Rochester, USA

other books by Konstantinos N. Syrigos

Immunology for Surgeons
Immunology for Surgeons

Kobo ebook|Dec 6 2012

$78.89 online$102.38list price(save 22%)
Format:HardcoverDimensions:366 pages, 9.69 × 7.44 × 0.98 inPublished:December 12, 2002Publisher:Oxford University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0198508964

ISBN - 13:9780198508960

Look for similar items by category:

Customer Reviews of Targeted Therapy for Cancer

Reviews

Extra Content

Table of Contents

Section I1. Bagshawe: The history of targeted therapy for cancer2. Rowlinson-Busza: Preclinical models for the study of targeted therapySection II3. Francis and Begent: Monoclonal antibody targeting therapy: an overview4. Syrigos and Harrington: Antibody-directed enzyme prodrug therapy (ADEPT)5. Batra, Goel, Pavlinkova and Colcher: Monoclonal antibody targeted radionuclide therapy6. Raben and Buchsbaum: Combined external beam radiotherapy and radioimmunotherapySection III7. Pandha: Genetic immunotherapy for cancer8. Harrington and Vile: Targeting of cancer gene therapy9. Rigg and Pandha: Targeted genetic prodrug activation therapy10. Waters and Cunningham: Antisense therapy as a targeted modality11. Melcher, Vile, Bateman and Harrington: Dendritic cells-targeting the antitumor immune response12. Diaz, Chong and Vile: Cell carriers for cancer gene therapy: bridging the gap between targeted vectors and systemic delivery?13. Harrington and Syrigos: Liposomal targeting of cytotoxic drugs14. Vidal, Cardo-Vila, Lahdenranta, Arap and Pasqualini: Targeting blood vessels in vivo by using phage display librariesSection IV15. Hamblin: Photodynamic therapy16. Morris and Coderre: Boron neutron capture therapy: a chemically targeted radiation modalitySection V17. Sela, Schecheter and Yarden: Cancer immunotherapy directed at growth factor receptors: the ErbB/HER network as a prototype18. Culp, Lin, Kleinman, Kogerman, Judware, Miller and Holleran: Targeting the metastatic process